3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
244
Melanoma
141
Squamous Cell Carcinoma of Head and Neck
139
Parkinson Disease 4, Autosomal Dominant Lewy Body
119
Neoplasm Metastasis
104
Triple Negative Breast Neoplasms
96
Neoplasms
91
Lung Neoplasms
91
Breast Neoplasms
81
Colorectal Neoplasms
70
Carcinoma, Renal Cell
69
Head and Neck Neoplasms
59
Urinary Bladder Neoplasms
50
Stomach Neoplasms
47
Ovarian Neoplasms
46
Endometrial Neoplasms
46
Carcinoma, Transitional Cell
44
Carcinoma, Hepatocellular
35
Uterine Cervical Neoplasms
34
Pancreatic Neoplasms
34
Esophageal Neoplasms
27
Prostatic Neoplasms
26
Recurrence
25
Carcinoma, Squamous Cell
25
Carcinoma
25
Sarcoma
24
Brain Neoplasms
24
Glioblastoma
23
Hodgkin Disease
19
Cholangiocarcinoma
19
Interventions
relatlimab
1
pembrolizumab
1
enfortumab vedotin
1
darolutamide
1
Watchful Waiting
1
Transurethral Resection of Prostate
1
Radiotherapy
1
Radiation Dose Hypofractionation
1
Pregnancy Tests
1
Nivolumab
1
Mitomycin
1
Human Papillomavirus DNA Tests
1
Gemcitabine
1
Fluorouracil
1
Colposcopy
1
Cisplatin
1
Biopsy
1
Acetic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Diseases
×
pembrolizumab
×
1 year
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled